Niraparib alone to help prevent cancer coming back
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 study tests niraparib by itself to keep endometrial serous cancer from returning or to control it after chemotherapy helps. It may help some people by targeting tumor DNA repair weaknesses, especially in cancers with certain gene changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re a woman age 18 or older
- You have a confirmed diagnosis of endometrial serous cancer (or another endometrial cancer) that is stage III or IV
- Your cancer has responded to certain prior platinum chemotherapy (or you have had more than two platinum treatments with a relapse, depending on the group)
- Your body is strong enough for treatment: ECOG 0–1, and key blood tests are high enough (neutrophils, platelets, hemoglobin)
- You must not have had a prior PARP inhibitor (this includes niraparib or similar drugs)
- You can’t be pregnant or breastfeeding, and you must use effective birth control if you can get pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This trial is testing a medication called niraparib (Zejula) for women with advanced or relapsed ovarian cancer. It may help keep the cancer from coming back after it has responded to platinum-based chemotherapy. The study focuses on safety and is for women who meet certain health and treatment criteria.
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
Hear when a new Endometrial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.